02457nas a2200337   4500000000100000000000100001008004100002260001200043653001200055653001300067653003500080653001100115653002600126653003400152653001500186653002300201653004000224653001600264653002000280653002000300653002600320100001800346700001600364700001700380700001600397245008900413300001000502490000700512520158600519022001402105       2021                            d  c2021-0110aAnimals10aCOVID-1910aCell- and Tissue-Based Therapy10aHumans10aRegenerative Medicine10aRespiratory Distress Syndrome10aSARS-CoV-210aTissue engineering10aacute respiratory distress syndrome10abiomaterial10acell processing10aclinical trials10amesenchymal stem cell1 aAbbas Shafiee1 aLida Moradi1 aMayasari Lim1 aJason Brown00aCoronavirus disease 2019: A tissue engineering and regenerative medicine perspective  a27-380 v103 aCurrent therapies for novel coronavirus disease (COVID-19) are generally used to manage rather than cure this highly infective disease. Therefore, there is a significant unmet medical need for a safe and effective treatment for COVID-19. Inflammation is the driving force behind coronavirus infections, and the majority of deaths caused by COVID-19 are the result of acute respiratory distress syndrome (ARDS). It is crucial to control the inflammation as early as possible. To date, numerous studies have been conducted to evaluate the safety and efficacy of tissue engineering and regenerative medicine (TERM) products, including mesenchymal stem cells (MSCs), and their derivatives (eg, exosomes) for coronavirus infections, which could be applied for the COVID-19. In this review, first, the impacts of the COVID-19 pandemic in the present and future of TERM research and products are briefly presented. Then, the recent clinical trials and the therapeutic benefits of MSCs in coronavirus-induced ARDS are critically reviewed. Last, recent advances in the field of tissue engineering relevant to coronavirus infections, including three-dimensional platforms to study the disease progression and test the effects of antiviral agents, are described. Moreover, the application of biomaterials for vaccine technology and drug delivery are highlighted. Despite promising results in the preclinical and clinical applications of MSC therapy for coronavirus infections, controversy still exists, and thus further investigation is required to understand the efficacy of these therapies.  a2157-6580